INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Intra-Cellular Therapies, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 11, 2017 – ITCI

NEW YORK, NY / ACCESSWIRE / May 22, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Intra-Cellular Therapies, Inc. (“Intra-Cellular Therapies”) (NASDAQ: ITCI) between August 12, 2014 and April 28, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Eastern District of New York. To get more information, go to: http://www.zlk.com/pslra-sb/intra-cellular-therapies-inc?wire=1, or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that, throughout the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; (2) and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On August 4, 2016, the Company’s CEO, Sharon Mates, touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” Then, on May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients.

If you suffered a loss in Intra-Cellular Therapies, you have until July 11, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 463867